Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Drug and Chemical Toxicology|November 14, 2020
Neurotoxicity of poly(propylene imine) glycodendrimersIda Franiak-Pietryga, Barbara Ziemba, Hanna Sikorska, et al.
Journal of Biomedical Materials Research. Part A|May 25, 2012
Influence of fourth generation poly(propyleneimine) dendrimers on blood cellsBarbara Ziemba, Inessa Halets, Dzmitry Shcharbin, et al.
Anti-Cancer Agents in Medicinal Chemistry|November 19, 2019
Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic LeukemiaBarbara Ziemba, Hanna Sikorska, Magdalena Jander, et al.
Journal of Biomedical Materials Research. Part A|October 7, 2011
In vivo toxicity of poly(propyleneimine) dendrimersBarbara Ziemba, Anna Janaszewska, Karol Ciepluch, et al.
Macromolecular Bioscience|December 21, 2016
PPI-G4 Glycodendrimers Upregulate TRAIL-Induced Apoptosis in Chronic Lymphocytic Leukemia CellsIda Franiak-Pietryga, Kinga Ostrowska, Henryk Maciejewski, et al.
International Journal of Pharmaceutics|December 24, 2013
Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: considering their contrary potential as biocompatible entity and drug molecule in cancerBarbara Ziemba, Ida Franiak-Pietryga, Marjorie Pion, et al.
Toxicology and Applied Pharmacology|August 21, 2018
Affecting NF-κB cell signaling pathway in chronic lymphocytic leukemia by dendrimers-based nanoparticlesIda Franiak-Pietryga, Kinga Ostrowska, Henryk Maciejewski, et al.
Macromolecular Bioscience|August 2, 2017
Blockage of Wnt/β-Catenin Signaling by Nanoparticles Reduces Survival and Proliferation of CLL Cells In Vitro-Preliminary StudyIda Franiak-Pietryga, Henryk Maciejewski, Barbara Ziemba, et al.
Molecular Pharmaceutics|May 7, 2013
The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPIIda Franiak-Pietryga, Ewelina Ziółkowska, Barbara Ziemba, et al.
Toxicology and Applied Pharmacology|July 21, 2020
Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLLIda Franiak-Pietryga, Barbara Ziemba, Hanna Sikorska, et al.
Pageof 3